Risk stratification and prognostic value of multi-modal MRI-based radiomics for extranodal nasal-type NK/T-cell lymphoma

[1]  F. Bini,et al.  matRadiomics: A Novel and Complete Radiomics Framework, from Image Visualization to Predictive Model , 2022, J. Imaging.

[2]  M. G. Sabini,et al.  Robustness of PET Radiomics Features: Impact of Co-Registration with MRI , 2021, Applied Sciences.

[3]  R. Cannella,et al.  Hybrid descriptive‐inferential method for key feature selection in prostate cancer radiomics , 2021, Applied Stochastic Models in Business and Industry.

[4]  T. Wu,et al.  Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study , 2021, ESMO open.

[5]  A. Ng,et al.  Modern Radiotherapy for Extranodal Nasal-type NK/T-cell Lymphoma: Risk-adapted Therapy, Target Volume and Dose Guidelines from the International Lymphoma Radiation Oncology Group. , 2021, International journal of radiation oncology, biology, physics.

[6]  Chen Hu,et al.  First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. , 2020, Blood advances.

[7]  Chen Hu,et al.  Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study , 2020, American journal of hematology.

[8]  Weili Zhao,et al.  Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. , 2020, Cancer cell.

[9]  R. Tsang,et al.  Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making , 2020, Leukemia.

[10]  Gang Wu,et al.  Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG) , 2019, Leukemia & lymphoma.

[11]  Yolande Lievens,et al.  Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Gang Wu,et al.  Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma , 2019, JAMA network open.

[13]  Myeong-Jin Kim,et al.  Radiomics on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma , 2019, Clinical Cancer Research.

[14]  C. Simone,et al.  Unsupervised machine learning of radiomic features for predicting treatment response and overall survival of early stage non-small cell lung cancer patients treated with stereotactic body radiation therapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Gang Wu,et al.  Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  R. Farah,et al.  The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T‐cell lymphoma, nasal type, in the United States , 2017, Cancer.

[17]  Sin-Ho Jung,et al.  A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[18]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[19]  Wei Wang,et al.  Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. , 2015, Blood.

[20]  T. Wu,et al.  Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study , 2015, Leukemia.

[21]  S. Hyun,et al.  Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. , 2015, The Lancet. Haematology.

[22]  W. Xue,et al.  Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma , 2014, Nature Genetics.

[23]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[24]  Shulian Wang,et al.  Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. , 2012, Blood.

[25]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Xiao-li Feng,et al.  Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. , 2008, Blood.

[27]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Yoon-Koo Kang,et al.  Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Keunchil Park,et al.  Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Y. S. Lee,et al.  Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Itami,et al.  Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Shulian Wang,et al.  Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance. , 2017, International journal of radiation oncology, biology, physics.

[33]  Shulian Wang,et al.  Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .